drugset / Trial / NCT05414175

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

NCT05414175

Phase 3 Completed 38 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness, safety, and tolerability of a 30-week course of mavacamten and the long-term effects of mavacamten in Japanese participants with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

Timeline

Start
2022-08-19
Primary completion
2023-11-27
Completion
2025-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavacamten Small molecule